Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
cGMP levels are raised by 1.7–2.3 times at 1~100 nM for 10 minutes by Hcyb1[1]. Hcyb1 raises cGMP and cAMP levels at 1 nM for 24 hours[1]. In HT-22 cells, hcyb1(24 hours) treatment also raises CREB and BDNF phosphorylation levels[1]. In addition to increasing cGMP and cAMP buildup in HT-22 cells, Hcyb1 supports HT-22 cell viability[1]. In HT-22 cells, Hcyb1 has concentration- and time-dependent effects on cell viability[2].
|
---|---|
ln Vivo |
Hcyb1 (0.5, 1, and 2 mg/kg, ir) reduces immobility duration without changing locomotor activity in forced swimming and tail suspension tests[3].
|
Cell Assay |
Cell Proliferation Assay[1]
Cell Types: HT-22 cells Tested Concentrations: 1 pM, 0.01 nM, 0.1 nM, 1 nM, 0.01 μM, 0.1 μM, 1 μM, 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: The cell viability was Dramatically increased when treating HT-22 cells with Hcyb1 at concentrations of 0.1 nM and 1 nM for 24 hrs (hours). The time-dependent effects demonstrated that the cell viability was Dramatically increased from 12 to 24 hrs (hours) when treatment at concentration of 1 nM. The maximal effects peaked at 24 hrs (hours) after treatment. Western Blot Analysis[1] Cell Types: HT-22 cells Tested Concentrations: 1 nM Incubation Duration: 24 hrs (hours) Experimental Results: Induced a significant increase in the phosphorylation of CREB. BDNF expression was also Dramatically upregulated at the same concentration. |
Animal Protocol |
Animal/Disease Models: Male imprinting control region (ICR) mice, weighing between 20 and 25 g[3]
Doses: 0.5, 1, and 2 mg/kg Route of Administration: Gavage (ig) Experimental Results: demonstrated dose-dependent reduction in immobility time at doses of 0.5, 1, 2 mg/kg (ig). |
References |
[1]. Li Liu, et al. The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor. CNS Neurosci Ther. 2018 Jul;24(7):652-660.
[2]. Meng-Jia Zhu, et al. Phosphodiesterase 2 inhibitor Hcyb1 reverses corticosterone-induced neurotoxicity and depression-like behavior. Psychopharmacology (Berl). 2020 Nov;237(11):3215-3224. |
Molecular Formula |
C24H20N4O
|
---|---|
Molecular Weight |
380.44
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO :~62.5 mg/mL (~164.28 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6285 mL | 13.1427 mL | 26.2854 mL | |
5 mM | 0.5257 mL | 2.6285 mL | 5.2571 mL | |
10 mM | 0.2629 mL | 1.3143 mL | 2.6285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.